CL2019003420A1 - Compositions and methods for decreasing the expression of tau, useful for treating diseases associated with tau. (divisional request 201801652) - Google Patents
Compositions and methods for decreasing the expression of tau, useful for treating diseases associated with tau. (divisional request 201801652)Info
- Publication number
- CL2019003420A1 CL2019003420A1 CL2019003420A CL2019003420A CL2019003420A1 CL 2019003420 A1 CL2019003420 A1 CL 2019003420A1 CL 2019003420 A CL2019003420 A CL 2019003420A CL 2019003420 A CL2019003420 A CL 2019003420A CL 2019003420 A1 CL2019003420 A1 CL 2019003420A1
- Authority
- CL
- Chile
- Prior art keywords
- tau
- protein
- compositions
- methods
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE PROPORCIONAN EN ESTA SOLICITUD COMPOSICIONES Y MÉTODOS PARA DISMINUIR LA EXPRESIÓN DE PROTEÍNA Y ARNM TAU. ESTAS COMPOSICIONES Y MÉTODOS SON ÚTILES EN EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON TAU. PARTICULARMENTE, SE PROPORCIONAN EN LA PRESENTE SOLICITUD OLIGONUCLEÓTIDOS ANTISENTIDO QUE SE DIRIGEN A LA PROTEÍNA TAU ASOCIADA A MICROTÚBULO HUMANA (MAPT, CONFORME A SUS SIGLAS EN INGLÉS), COMPOSICIONES QUE COMPRENDEN LOS OLIGONUCLEÓTIDOS ANTISENTIDO, Y MÉTODOS PARA DISMINUIR LA EXPRESIÓN DE PROTEÍNA Y ARNM DE TAU USANDO ESTOS OLIGONUCLEÓTIDOS ANTISENTIDO. LAS COMPOSICIONES Y LOS MÉTODOS PROPORCIONADOS EN ESTE DOCUMENTO SON ÚTILES EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS A TAU.COMPOSITIONS AND METHODS TO DECREASE THE EXPRESSION OF PROTEIN AND TAU mRNA ARE PROVIDED IN THIS APPLICATION. THESE COMPOSITIONS AND METHODS ARE USEFUL IN THE TREATMENT OF TAU-RELATED DISEASES AND DISORDERS. PARTICULARLY, IN THIS APPLICATION, ANTI-SENSE OLIGONUCLEOTIDES ARE PROVIDED THAT TARGET THE TAU PROTEIN ASSOCIATED WITH THE HUMAN MICROTUBE (MAPT, ACCORDING TO ITS ACRONYMS IN ENGLISH), COMPOSITIONS THAT INCLUDE THE PROTEIN OF THE PROTEIN ASSOCIATED WITH THE HUMAN MICROTUBLE (MAPT, ACCORDING TO ITS ACRONYM IN ENGLISH), COMPOSITIONS THAT INCLUDE THE PROTEIN OF THE ANTI-PRINTED OLIGONUCLEOTIDE, AND THE EXPRESSED PROTEIN, AND THE EXPRESSED PROTEIN OF THE PROTEIN, AND THE EXPRESSION OF THE PROTEIN OF ANTI-PRINTED MISCELLANEOUS PROTEIN. TAU USING THESE ANTI-SENSE OLIGONUCLEOTIDES. THE COMPOSITIONS AND METHODS PROVIDED IN THIS DOCUMENT ARE USEFUL IN THE TREATMENT OF DISEASES ASSOCIATED WITH TAU.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562270165P | 2015-12-21 | 2015-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019003420A1 true CL2019003420A1 (en) | 2020-05-15 |
Family
ID=57758674
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018001652A CL2018001652A1 (en) | 2015-12-21 | 2018-06-18 | Compositions and methods to reduce tau expression |
CL2019000149A CL2019000149A1 (en) | 2015-12-21 | 2019-01-18 | Compositions and methods to reduce the expression of tau, useful for treating diseases associated with tau. (divisional application 201801652) |
CL2019003420A CL2019003420A1 (en) | 2015-12-21 | 2019-11-25 | Compositions and methods for decreasing the expression of tau, useful for treating diseases associated with tau. (divisional request 201801652) |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018001652A CL2018001652A1 (en) | 2015-12-21 | 2018-06-18 | Compositions and methods to reduce tau expression |
CL2019000149A CL2019000149A1 (en) | 2015-12-21 | 2019-01-18 | Compositions and methods to reduce the expression of tau, useful for treating diseases associated with tau. (divisional application 201801652) |
Country Status (32)
Country | Link |
---|---|
US (2) | US11473083B2 (en) |
EP (1) | EP3394259B1 (en) |
JP (3) | JP7027328B2 (en) |
KR (1) | KR20180089517A (en) |
CN (2) | CN116218848A (en) |
AR (1) | AR107579A1 (en) |
AU (2) | AU2016376034B2 (en) |
BR (1) | BR112018012304A2 (en) |
CA (1) | CA3008094A1 (en) |
CL (3) | CL2018001652A1 (en) |
CO (1) | CO2018006297A2 (en) |
CR (1) | CR20200609A (en) |
CU (1) | CU24574B1 (en) |
DK (1) | DK3394259T3 (en) |
DO (1) | DOP2018000151A (en) |
EA (2) | EA036417B1 (en) |
EC (1) | ECSP18050575A (en) |
FI (1) | FI3394259T3 (en) |
HK (1) | HK1254822A1 (en) |
IL (3) | IL296844B2 (en) |
JO (2) | JOP20200228A1 (en) |
MX (2) | MX2018007726A (en) |
MY (1) | MY191737A (en) |
PE (1) | PE20181448A1 (en) |
PH (1) | PH12018501207A1 (en) |
RU (1) | RU2747734C2 (en) |
SA (1) | SA518391831B1 (en) |
SG (2) | SG11201804704PA (en) |
SV (1) | SV2018005714A (en) |
TW (1) | TWI787163B (en) |
UY (1) | UY37038A (en) |
WO (1) | WO2017109679A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013148260A1 (en) | 2012-03-30 | 2013-10-03 | Washington University | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
TW202246503A (en) | 2013-07-19 | 2022-12-01 | 美商百健Ma公司 | Compositions for modulating tau expression |
JOP20190065A1 (en) | 2016-09-29 | 2019-03-28 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing tau expression |
MX2020009532A (en) * | 2018-03-13 | 2020-10-05 | Janssen Pharmaceutica Nv | Modified oligonucleotides for use in treatment of tauopathies. |
KR20230143199A (en) | 2018-07-03 | 2023-10-11 | 에프. 호프만-라 로슈 아게 | Oligonucleotides for modulating tau expression |
CN116234585A (en) * | 2020-03-30 | 2023-06-06 | 阿尔尼拉姆医药品有限公司 | Microtubule-associated protein TAU (MAPT) iRNA agent compositions and methods of use thereof |
CN113817728A (en) * | 2020-06-19 | 2021-12-21 | 四川大学华西医院 | Recombinant lentivirus capable of effectively interfering Tau protein expression and application thereof |
KR20240034185A (en) * | 2021-06-16 | 2024-03-13 | 엠피리코 인크. | Treatment of MTRES1-related diseases and disorders |
WO2024091874A1 (en) * | 2022-10-25 | 2024-05-02 | Empirico Inc. | Gene therapy treatment of mtres1 related diseases and disorders |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
AU651569B2 (en) | 1990-01-11 | 1994-07-28 | Isis Pharmaceuticals, Inc. | Compositions and methods for detecting and modulating RNA activity and gene expression |
US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
US20020052331A1 (en) | 1990-08-14 | 2002-05-02 | Brenda Baker | Compositions and methods for antisense inhibition of protein translation |
US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
DK0618968T3 (en) | 1991-12-06 | 2000-04-10 | Max Planck Gesellschaft | Means for diagnosing and treating Alzheimer's disease |
US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
CA2116460A1 (en) | 1993-03-02 | 1994-09-03 | Mitsubishi Chemical Corporation | Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being |
KR940021073A (en) | 1993-03-02 | 1994-10-17 | 미야베 요시가즈 | Prophylactic or therapeutic agents for Alzheimer's disease, methods for screening the same, and tau protein kinase I derived from humans |
JPH08510130A (en) | 1993-05-11 | 1996-10-29 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Antisense oligonucleotides that inhibit aberrant splicing and methods of using the same |
BR9707529A (en) | 1996-02-14 | 2000-01-04 | Isis Pharmaceuticals Inc | Oligunucleotide specifically hybridized with DNA or RNA. |
JP3756313B2 (en) | 1997-03-07 | 2006-03-15 | 武 今西 | Novel bicyclonucleosides and oligonucleotide analogues |
NZ503765A (en) | 1997-09-12 | 2002-04-26 | Exiqon As | Bi-cyclic and tri-cyclic nucleotide analogues |
US20040186071A1 (en) | 1998-04-13 | 2004-09-23 | Bennett C. Frank | Antisense modulation of CD40 expression |
CA2330944A1 (en) | 1998-05-01 | 1999-11-11 | Mayo Foundation For Medical Education And Research | Pathogeniv tau mutations |
US6664443B1 (en) | 1998-05-01 | 2003-12-16 | Mayo Foundation For Medical Education And Research | Pathogenic Tau mutations in transgenic mice |
CZ2001149A3 (en) * | 1998-07-14 | 2002-02-13 | Corixa Corporation | Preparations and methods for therapy and diagnostic of prostate carcinoma |
US7098192B2 (en) * | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
WO2000064262A1 (en) | 1999-04-26 | 2000-11-02 | The University Of North Carolina At Chapel Hill | Antisense human fucosyltransferase sequences and methods of use thereof |
CN101284873A (en) * | 1999-06-30 | 2008-10-15 | 科里克萨有限公司 | Compositions and methods for the therapy and diagnosis of lung cancer |
WO2001053340A2 (en) | 2000-01-21 | 2001-07-26 | Pharmacia & Upjohn Company | Transgenic mouse model of human neurodegenerative disease |
CA2400595A1 (en) * | 2000-02-28 | 2001-09-07 | Decode Genetics Ehf | Human schizophrenia gene |
AU2002231741A1 (en) | 2001-01-11 | 2002-07-24 | Bayer Aktiengesellschaft | Regulation of human tau-tubulin kinase |
US20050130924A1 (en) | 2002-06-26 | 2005-06-16 | Monia Brett P. | Antisense inhibition via RNAse H-independent reduction in mRNA |
WO2004003134A2 (en) | 2002-06-26 | 2004-01-08 | Isis Pharmaceuticals, Inc. | Antisense inhibition via rnase h-independent reduction in mrna |
US20080176812A1 (en) | 2002-08-05 | 2008-07-24 | Davidson Beverly L | Allele-specific silencing of disease genes |
US20050106731A1 (en) | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
US20040241854A1 (en) | 2002-08-05 | 2004-12-02 | Davidson Beverly L. | siRNA-mediated gene silencing |
WO2004016655A1 (en) | 2002-08-14 | 2004-02-26 | Mitsubishi Chemical Corporation | ANTIBODY SPECIFIC TO CENTRAL τ-PROTEIN |
US8163896B1 (en) | 2002-11-14 | 2012-04-24 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
US7906326B2 (en) | 2003-05-07 | 2011-03-15 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides associated with alzheimer's disease and uses thereof |
US20130130231A1 (en) | 2002-11-26 | 2013-05-23 | Isaac Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
US20060257851A1 (en) | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
US7696334B1 (en) | 2002-12-05 | 2010-04-13 | Rosetta Genomics, Ltd. | Bioinformatically detectable human herpesvirus 5 regulatory gene |
US20070077553A1 (en) | 2003-10-30 | 2007-04-05 | Rosetta Genomics | Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof |
US7790867B2 (en) | 2002-12-05 | 2010-09-07 | Rosetta Genomics Inc. | Vaccinia virus-related nucleic acids and microRNA |
US7888497B2 (en) | 2003-08-13 | 2011-02-15 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
AU2003904328A0 (en) | 2003-08-13 | 2003-08-28 | Garvan Institute Of Medical Research | Diagnosis and treatment of neurodegenerative disorders |
AU2004269150C1 (en) | 2003-08-28 | 2010-11-18 | Novartis Ag | Interfering RNA duplex having blunt-ends and 3'-modifications |
WO2005040382A2 (en) | 2003-10-28 | 2005-05-06 | Alexander Cherkasky | Cherkasky fusion proteins containing antibody-, antigen- and microtubule-binding regions and immune response-triggering regions |
US20050244851A1 (en) | 2004-01-13 | 2005-11-03 | Affymetrix, Inc. | Methods of analysis of alternative splicing in human |
CA2566519C (en) * | 2004-05-14 | 2020-04-21 | Rosetta Genomics Ltd. | Micrornas and uses thereof |
US7687616B1 (en) | 2004-05-14 | 2010-03-30 | Rosetta Genomics Ltd | Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof |
EP4047096A1 (en) | 2004-06-28 | 2022-08-24 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US7312035B2 (en) | 2004-09-03 | 2007-12-25 | Affymetrix, Inc. | Methods of genetic analysis of yeast |
US7838657B2 (en) | 2004-12-03 | 2010-11-23 | University Of Massachusetts | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
WO2006060753A2 (en) | 2004-12-03 | 2006-06-08 | Rhode Island Hospital | Diagnosis and treatment of alzheimer's disease |
US20070048756A1 (en) | 2005-04-18 | 2007-03-01 | Affymetrix, Inc. | Methods for whole genome association studies |
EP1937312B1 (en) | 2005-08-30 | 2016-06-29 | Ionis Pharmaceuticals, Inc. | Chimeric oligomeric compounds for modulation of splicing |
WO2007047913A2 (en) | 2005-10-20 | 2007-04-26 | Isis Pharmaceuticals, Inc | Compositions and methods for modulation of lmna expression |
GB0605337D0 (en) | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
US7901882B2 (en) | 2006-03-31 | 2011-03-08 | Affymetrix, Inc. | Analysis of methylation using nucleic acid arrays |
CA3042781C (en) | 2006-04-03 | 2021-10-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
US20090280110A1 (en) | 2006-06-27 | 2009-11-12 | University Of Virginia Patent Foundation | Cell Model for Alzheimer's Disease Pathology |
AU2007323469B2 (en) | 2006-11-23 | 2014-07-24 | Guangdong Maijinjia Biotechnology Co., Ltd | Oligonucleotides for modulating target RNA activity |
CA2682497C (en) | 2007-04-05 | 2017-08-08 | The J. David Gladstone Institutes | Agents that reduce neuronal overexcitation |
JP2008307007A (en) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth |
WO2009109665A1 (en) | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
ES2599979T3 (en) | 2009-04-24 | 2017-02-06 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for the treatment of HCV patients who do not respond to interferon |
CN103003430A (en) | 2009-11-12 | 2013-03-27 | 西澳大利亚大学 | Antisense molecules and methods for treating pathologies |
WO2011094645A1 (en) | 2010-01-28 | 2011-08-04 | University Of Massachusetts Lowell | Methods of diagnosing tau-associated neurodegenerative diseases |
WO2011117353A1 (en) | 2010-03-24 | 2011-09-29 | Mirrx Therapeutics A/S | Bivalent antisense oligonucleotides |
AU2011325956B2 (en) | 2010-11-12 | 2016-07-14 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
US9145557B2 (en) | 2010-11-23 | 2015-09-29 | Mirrx Therapeutics A/S | Oligonucleotides for modulation of target RNA activity |
EP2655621B1 (en) | 2010-12-20 | 2018-05-23 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
WO2012149438A1 (en) * | 2011-04-28 | 2012-11-01 | Life Technologies Corporation | Methods and compositions for multiplex pcr |
WO2013013165A2 (en) | 2011-07-21 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus |
WO2013148260A1 (en) * | 2012-03-30 | 2013-10-03 | Washington University | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
AU2013243946A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
JP6321633B2 (en) | 2012-06-04 | 2018-05-09 | ノバルティス アーゲー | Site-specific labeling method and molecules produced thereby |
WO2014064187A1 (en) | 2012-10-24 | 2014-05-01 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | A microtubuli-modifying compound |
US9200068B2 (en) | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
KR20150099804A (en) | 2012-12-20 | 2015-09-01 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | Improved exon skipping compositions for treating muscular dystrophy |
EA202090946A3 (en) | 2013-03-14 | 2021-07-30 | Сарепта Терапьютикс, Инк. | COMPOSITIONS PROVIDING EXONE LEAKING FOR THE TREATMENT OF MUSCLE DYSTROPHY |
US9644207B2 (en) | 2013-03-14 | 2017-05-09 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating Tau expression |
CA2903872A1 (en) | 2013-03-14 | 2014-09-25 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
CA2951816A1 (en) | 2013-06-12 | 2014-12-18 | Oncoimmunin, Inc. | Systemic in vivo delivery of oligonucleotides |
TW202246503A (en) * | 2013-07-19 | 2022-12-01 | 美商百健Ma公司 | Compositions for modulating tau expression |
WO2015068075A2 (en) | 2013-10-24 | 2015-05-14 | Institut National De La Sante Et De La Recherche Medicale | Detection of tau |
WO2016011123A1 (en) * | 2014-07-16 | 2016-01-21 | Arrowhead Research Corporation | Organic compositions to treat apoc3-related diseases |
US20170211064A1 (en) | 2014-07-29 | 2017-07-27 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating tau expression |
EP3254104B1 (en) | 2015-02-04 | 2021-08-25 | Bristol-Myers Squibb Company | Methods of selecting therapeutic molecules |
US20180023081A1 (en) | 2015-02-04 | 2018-01-25 | Bristol-Myers Squibb Company | Lna oligonucleotides with alternating flanks |
AU2016215155A1 (en) * | 2015-02-04 | 2017-08-17 | F. Hoffmann-La Roche Ag | Tau antisense oligomers and uses thereof |
US20170035860A1 (en) * | 2015-04-02 | 2017-02-09 | Alexander C. Flynn | Compositions and methods for treatment of neurogenerative diseases |
-
2015
- 2015-12-21 JO JOP/2020/0228A patent/JOP20200228A1/en unknown
-
2016
- 2016-12-19 KR KR1020187020632A patent/KR20180089517A/en not_active Application Discontinuation
- 2016-12-19 TW TW105142107A patent/TWI787163B/en active
- 2016-12-19 JP JP2018550880A patent/JP7027328B2/en active Active
- 2016-12-19 FI FIEP16823350.0T patent/FI3394259T3/en active
- 2016-12-19 US US15/383,452 patent/US11473083B2/en active Active
- 2016-12-19 WO PCT/IB2016/057794 patent/WO2017109679A1/en active Application Filing
- 2016-12-19 AU AU2016376034A patent/AU2016376034B2/en active Active
- 2016-12-19 CR CR20200609A patent/CR20200609A/en unknown
- 2016-12-19 BR BR112018012304A patent/BR112018012304A2/en active Search and Examination
- 2016-12-19 DK DK16823350.0T patent/DK3394259T3/en active
- 2016-12-19 CN CN202211714988.9A patent/CN116218848A/en active Pending
- 2016-12-19 IL IL296844A patent/IL296844B2/en unknown
- 2016-12-19 CU CU2018000065A patent/CU24574B1/en unknown
- 2016-12-19 EP EP16823350.0A patent/EP3394259B1/en active Active
- 2016-12-19 IL IL305866A patent/IL305866A/en unknown
- 2016-12-19 JO JOP/2016/0266A patent/JO3790B1/en active
- 2016-12-19 SG SG11201804704PA patent/SG11201804704PA/en unknown
- 2016-12-19 CN CN201680082326.0A patent/CN109072237B/en active Active
- 2016-12-19 SG SG10201913434PA patent/SG10201913434PA/en unknown
- 2016-12-19 MY MYPI2018702190A patent/MY191737A/en unknown
- 2016-12-19 PE PE2018001176A patent/PE20181448A1/en unknown
- 2016-12-19 EA EA201891468A patent/EA036417B1/en not_active IP Right Cessation
- 2016-12-19 CA CA3008094A patent/CA3008094A1/en active Pending
- 2016-12-19 UY UY0001037038A patent/UY37038A/en active IP Right Grant
- 2016-12-19 RU RU2018126545A patent/RU2747734C2/en active
- 2016-12-19 EA EA202091865A patent/EA202091865A1/en unknown
- 2016-12-19 MX MX2018007726A patent/MX2018007726A/en unknown
- 2016-12-19 AR ARP160103917A patent/AR107579A1/en unknown
-
2018
- 2018-06-07 PH PH12018501207A patent/PH12018501207A1/en unknown
- 2018-06-18 CO CONC2018/0006297A patent/CO2018006297A2/en unknown
- 2018-06-18 CL CL2018001652A patent/CL2018001652A1/en unknown
- 2018-06-18 IL IL260124A patent/IL260124A/en unknown
- 2018-06-18 SV SV2018005714A patent/SV2018005714A/en unknown
- 2018-06-19 SA SA518391831A patent/SA518391831B1/en unknown
- 2018-06-20 DO DO2018000151A patent/DOP2018000151A/en unknown
- 2018-06-21 MX MX2023008211A patent/MX2023008211A/en unknown
- 2018-07-05 EC ECSENADI201850575A patent/ECSP18050575A/en unknown
- 2018-10-31 HK HK18113913.7A patent/HK1254822A1/en unknown
-
2019
- 2019-01-18 CL CL2019000149A patent/CL2019000149A1/en unknown
- 2019-11-25 CL CL2019003420A patent/CL2019003420A1/en unknown
-
2020
- 2020-11-13 AU AU2020267282A patent/AU2020267282B2/en active Active
-
2021
- 2021-04-28 JP JP2021076622A patent/JP2021118732A/en active Pending
-
2022
- 2022-02-15 JP JP2022021494A patent/JP2022065096A/en active Pending
- 2022-07-20 US US17/813,843 patent/US20220411796A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019003420A1 (en) | Compositions and methods for decreasing the expression of tau, useful for treating diseases associated with tau. (divisional request 201801652) | |
BR112018072279A2 (en) | oligonucleotide analogues targeting human lmna | |
CO2017007671A2 (en) | Compositions to modulate c9orf72 expression | |
CL2018001384A1 (en) | Biparatopic polypeptides that antagonize wnt signaling in tumor cells | |
CL2020003028A1 (en) | Anti-cd33 antibodies, anti-cd33 / anti-cd3 bispecific antibodies and their uses. | |
PE20180243A1 (en) | COMPOSITIONS INCLUDING BACTERIAL STRAINS | |
CO2017009008A2 (en) | Tau antisense oligomers | |
ECSP19070336A (en) | THERAPEUTIC RNA | |
CO2017011484A2 (en) | Bromodomain inhibitors | |
CO2019003846A2 (en) | Aav treatment of huntington's disease | |
BR112018073861A2 (en) | Gene therapy methods for age-related diseases and conditions | |
CL2017001960A1 (en) | Methods of treating inflammatory diseases | |
CO2017008940A2 (en) | Il-18 (il-18bp) binding protein and antibodies in inflammatory diseases | |
CL2019003419A1 (en) | Polypeptides that antagonize wnt signaling in tumor cells. | |
CL2019003270A1 (en) | Octahydrophenanthrene-bis carboxamides and protein conjugates. | |
CL2018000597A1 (en) | Methods to treat inflammatory diseases | |
CL2018002810A1 (en) | Anti-complement factor bb antibodies and uses of these cross-reference. | |
NI201801172A (en) | NEW COMPOUNDS FOR THE TREATMENT OF PARASITIC DISEASES | |
BR112018068798A2 (en) | compositions and methods for treating parasitic diseases | |
BR112018012347A2 (en) | method for the manufacture of a single stream sparkling composition, sparkling composition and method for treating an individual having, or at risk of having, a corticosteroid-responsive condition | |
MX2020003565A (en) | Cornulin (crnn) variants and uses thereof. | |
CL2019003074A1 (en) | Variants of the human bmp7 protein. | |
AR110113A1 (en) | ANTI-SELECTINE ANTIBODY AND ITS USES | |
DOP2019000220A (en) | THERAPEUTIC RNA |